Adjuvant postoperative radiation therapy for rectal adenocarcinoma.

Published

Journal Article

From October 1975 to August 1988, 261 patients at high risk for local recurrence after curative resection of rectal carcinoma underwent high-dose postoperative irradiation. Patients received 45 Gy by a 4-field box usually followed by a boost to 50.4 Gy or higher when small bowel could be excluded from the reduced field. Since January 1986, patients also received 5-fluorouracil (5-FU) for 3 consecutive days during the first and last week of radiotherapy. Five-year actuarial local control and disease-free survival decreased with increasing stage of disease; patients with Stage B2 and B3 disease had local control rates of 83% and 87% and disease-free survivals of 55% and 74%, respectively. In patients with Stage C1 through C3 tumors, local control rates ranged from 76% to 23%, and disease-free survivals ranged from 62% to 10%, respectively. For patients with Stage C disease, disease-free survival decreased progressively with increasing lymph node involvement, but local control was independent of the extent of lymph node involvement. For each stage of disease, local control and disease-free survival did not correlate with the dose of pelvic irradiation. Preliminary data from this study suggest a trend toward improved local control for patients with Stage B2, C1, and C2 tumors who receive 5-FU for 3 consecutive days during the first and last weeks of irradiation compared with patients who do not receive 5-FU. Current prospective randomized studies are addressing questions regarding the optimum administration of chemotherapy with pelvic irradiation for patients following resection of rectal carcinoma.

Full Text

Duke Authors

Cited Authors

  • Willett, CG; Tepper, JE; Kaufman, DS; Shellito, PC; Eliseo, R; Convery, K; Wood, WC

Published Date

  • October 1992

Published In

Volume / Issue

  • 15 / 5

Start / End Page

  • 371 - 375

PubMed ID

  • 1524036

Pubmed Central ID

  • 1524036

International Standard Serial Number (ISSN)

  • 0277-3732

Language

  • eng

Conference Location

  • United States